Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Post by MrMugsyon Jan 10, 2023 12:04pm
186 Views
Post# 35213579

Thanks Golden ...

Thanks Golden ...Did listen to Biogen's CEO speak about the Alzheimer's drug.
Far from a sure thing - lots of hurdles.
He's positive about it but that's his job.
Getting medicare coverage isn't a sure thing either - could be months in the works or years in the making.
Don't even know what % would be covered - if it gets that far.

Regardless - Exelon in pill or patch form isn't going to have to worry about infusion as a competitor.
That's my opinion.

Tag this comment and see if I'm right in 5 years.  Hahaha !

<< Previous
Bullboard Posts
Next >>